Welcome to the e-CCO Library!

P424 Economic evaluation of vedolizumab SC for the treatment of moderate-to-severe ulcerative colitis in Canada
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. FISCHER1, M. Oppe2, S. Stypa1, V. Lukyanov3, I. Petrakis4

Created: Thursday, 30 January 2020, 10:12 AM
P424: Association between infliximab trough levels, clinical remission, mucosal healing and quality of life in patients with inflammatory bowel disease on maintenance therapy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Parra R.S., Feitosa M.R., Féres O., Rocha J.J.R.d.

Created: Wednesday, 20 February 2019, 10:36 AM
P424: Do antiTNF through levels correlate with joint extraintestinal manifestations (EIM) activity in Inflammatory bowel disease (IBD) patients?
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Madero Velázquez, L.(1)*;Jovani, V.(2);Andrés, M.(3);Más, P.(4);Aguas, M.(5);Vicens, E.(6);Ojeda, A.(7);Noguera-Pons, J.R.(8);Ranieri, L.(9);Zabana, Y.(10);Pujol, M.(11);Barreiro de Acosta, M.(12);Pérez-Pampin, E.(13);Bernal, L.(14);Belen, O.(14);Moreno, V.(14);García, M.F.(15);Sempere, L.(1);Zapater, P.(16);Gutiérrez Casbas, A.(17);
Created: Friday, 14 July 2023, 11:05 AM
P424: Is the switch to a second thiopurine a safe strategy in elderly patients with inflammatory bowel disease? A multi-centre cohort study of the ENEIDA registry
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Calafat*1, M. Mañosa1,2, E. Ricart2,3, E. Iglesias4, M. Calvo5, F. Rodríguez-Moranta6, C. Taxonera7, P. Nos2,8, F. Mesonero9, M. Martín-Arranz10, M. Mínguez11, J. P. Gisbert2,12, S. García-López13, R. de Francisco14, F. Gomollón2,15, X. Calvet2,16, E. García-Planella17, M. Rivero18, J. Martínez-Cadila19, F. Argüelles20, L. Arias21, M. Cimavilla22, Y. Zabana2,23, F. Cañete1,2, E. Cabré1,2, E. Domènech1,2, ENEIDA Registry of GETECCU1

Created: Friday, 22 February 2019, 9:41 AM
P424: Monitoring response to adalimumab therapy in Crohn’s disease patients by bowel ultrasound: Sub-analysis from TRUST
Year: 2018
Source: ECCO '18 Vienna
Authors:

T. Kucharzik1*, C. Maaser2, U. Helwig3, N. Börner4, J. Gronych5, A. Rössler5, S. Rath5, TRUST Study Group

Created: Thursday, 21 February 2019, 9:14 AM
P424: Surgery for children with Crohn’s disease.
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Stefanowicz*1, H. Ismail1, G. Kowalewski1, A. Kowalski1, J. Kierkuś2, P. Kaliciński1

Created: Friday, 22 February 2019, 9:49 AM
P424: Treatment persistence of first-line anti-TNF therapy in patients with inflammatory bowel diseases: results from a real-world study over 20 years
Year: 2021
Source: ECCO'21 Virtual
Authors: Blesl, A.(1);Binder, L.(1);Högenauer, C.(1);Wenzl, H.(1);Borenich, A.(2);Pregartner, G.(2);Berghold, A.(2);Mestel, S.(1);Kump, P.(1);Baumann-Durchschein, F.(1);Petritsch, W.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P424: Uptake of a switching program for patients receiving intravenous infliximab and vedolizumab to subcutaneous preparations
Year: 2022
Source: ECCO'22
Authors: Alice, H.(1);Gemma, B.(1);Selinger, C.P.(1);
Created: Friday, 11 February 2022, 3:52 PM
P425 SPOSIB SB2: a Sicilian prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar SB2
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F.S. Macaluso1, W. Fries2, A. Viola2, A. Centritto2, M. Cappello3, E. Giuffrida3, A.C. Privitera4, G. Piccillo4, A. Magnano5, E. Vinci5, R. Vassallo6, A. Trovatello7, N. Belluardo8, E. Giangreco8, S. Camilleri9, S. Garufi9, C. Bertolami10, M. Ventimiglia1, S. Renna1, R. Orlando1, G. Rizzuto1, M. Grova1, A. Orlando1

Created: Thursday, 30 January 2020, 10:12 AM
P425: Biosimilar infliximab in real-life Crohn's disease treatment in anti-TNF-alpha naïve and non-naïve patients in comparison to biologic originator: a comparative observational cohort study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kaniewska M.*1, Moniuszko A.1, Maciejewska K.1, Rydzewska G.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
P425: Comparison of therapeutic choices in biologic experienced Crohn’s disease and ulcerative colitis patients in Europe: discontinuation rates because of disease improvements
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Franceschetti*1, A. Baskett2, H. McKenzie2

Created: Friday, 22 February 2019, 9:49 AM
P425: Development of an enzyme-linked immunosorbent assay for therapeutic drug monitoring of ustekinumab
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Farrag*1,2, M. Rohlfs3, J. Ruppert3, F-P. Armbruster3, J. Stein1,2

Created: Friday, 22 February 2019, 9:41 AM
P425: Proactive measurement of infliximab trough levels vs. clinical management in inflammatory bowel disease: multicentre study
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Elosua González1*, D. Oyón Lara1, P. Sanz Segura2, M. Arroyo Villariño3, S. García López2, C. Rodríguez Gutiérrez1, Ó. Nantes Castillejo1

Created: Thursday, 21 February 2019, 9:14 AM
P425: Rates of tuberculosis infection in Crohn’s Disease patients before and during anti-tumor necrosis factor therapy
Year: 2022
Source: ECCO'22
Authors: GeorgievaPhD, A.C.(1);Atanassova, A.(1);Mirchev, M.(1);
Created: Friday, 11 February 2022, 3:52 PM
P425: Real-world evidence on effectiveness and safety of vedolizumab therapy for inflammatory bowel disease in Taiwan: Results from the TSIBD registry (VIOLET Study)
Year: 2021
Source: ECCO'21 Virtual
Authors: Wei , S.C.(1);Lin , W.C.(2);Chang , C.H.(3);Tu , C.H.(1);Feng , I.C.(4);Shieh , M.J.(5);Chung , C.S.(6);Yen , H.H.(7);Chou , J.W.(8);Tai , W.C.(9);Wong , J.M.(1);Liu , Y.H.(10);Huang , T.Y.(11);Chuang , C.H.(12);Tsai , T.J.(13);Chiang , F.F.(14);Lu , C.Y.(15);Hsu , W.H.(15);Yu , F.J.(15);Chao , T.H.(14);Wu , D.C.(15);Ho , A.S.(16);Lin , H.H.(17);Feng , C.L.(18);Wu , K.L.(9);Wong , M.W.(19);Tung , C.C.(20);Lin , C.C.(17);Chen , C.C.(3);Hu , H.M.(21);Lu , L.S.(22);Wang , H.S.(23);Wu , I.C.(15);Kuo , H.Y.(24,25);Wu , J.F.(26);Shih , H.Y.(15);Ni , Y.H.(27);Tang , S.L.(28);Chang , H.C.(28);Chen , P.H.(28);
Created: Wednesday, 2 June 2021, 4:12 PM
P425: The utility of intestinal ultrasound to inform clinical decision making
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Yeaman, F.(1)*;Panaccione, R.(1);Ma, C.(1);Lu, C.(1);Seow, C.(1);Kaplan, G.(1);Maracle, B.(1);Novak, K.(1);
Created: Friday, 14 July 2023, 11:05 AM
P426 In failure of non-optimised adalimumab (ADA) with therapeutic serum levels, a change in biotherapy class is greater than an intensification of ADA dose in IBD patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

X. Roblin1, C. genin1, N. williet1, P. veyrard1, G. boschetti2, A.E. berger3, B. flourie2, S. nancey2, S. Paul3

Created: Thursday, 30 January 2020, 10:12 AM
P426: Association Between vedolizumab therapy outcome and Pre-treatment DUBLIN Score & CRP-Albumin Ratio in Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: McCormick, E.(1);Singh, P.(1);Kevans, D.(1);
Created: Friday, 11 February 2022, 3:52 PM
P426: Health-Related Quality of Life and Work Productivity in patients with moderate-to-severe Inflammatory Bowel Disease in Argentina: Data from the RISE AR study
Year: 2021
Source: ECCO'21 Virtual
Authors: Correa, G.J.(1);Yantorno, M.(1);Olivera Sendra, P.(2,3);Lasa, J.S.(2,4);Lubrano, P.(3);Balderramo, D.C.(5,6);Zubiaurre, I.(4);Ruffinengo, O.(7);Brion, L.(8);Leonardi, D.B.(8);El-Hakeh, J.(8);Guimaraens, P.N.(8);Sambuelli, A.(9);
Created: Wednesday, 2 June 2021, 4:12 PM
P426: Lympocytosis in patients with inflammatory bowel disease treated with anti-TNFa agents: is it significant?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Soufleris*1, N. Kafalis1, M. Charalampidis1, K. Fasoulas1, I. Pilpilidis1, G. Lazaraki1, D. Tzilves1, D. Markala2

Created: Friday, 22 February 2019, 9:41 AM